The latest announcement is out from Cue Biopharma ( (CUE) ).
Oct 13 (Reuters) - The U.S. government has awarded diagnostic testing company Cue Health Inc $481 million to scale up the production of rapid COVID-19 molecular test, the Department of Health and ...
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures ...